Esketamine nasal spray compassionate use program in the Netherlands: An open label, multi-center cohort study in severe treatment-resistant depression

Esketamine nasal spray compassionate use program in the Netherlands: An open label, multi-center cohort study in severe treatment-resistant depression

Background: Esketamine, a N-methyl-d-aspartate (NMDA) receptor antagonist, used intranasally (IN), is applied as an antidepressant (AD) in treatment-resistant depressed (TRD) patients. Real-world studies with IN esketamine are still scarce. Objectives: To evaluate the effectiveness and potential mod...

Full description

Saved in:
Bibliographic Details
Main Authors: Abel (K.A.J.) Busz, Emma (E.J.) Schmidt, Rob (R.H.S.) van den Brink, Karen (K.) Foeken, Marasha (M.) de Jong, Joost (J.B.C.) Mertens, Martijn (M.S.) van Noorden, Etienne (E.J.F.L.) Olivier, Koen (K.R.J.) Schruers, Sara (S.I.J.) Schutters, Joris (J.) van Son, Wessel (W.J.) Strootker, Harry (H.C.P.) Venema, Dieuwertje (D.A.) de Waardt, Jasper (J.B.) Zantvoord, Danielle (D.) Cath, Henricus (H.G.) Ruhe
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Journal of Affective Disorders Reports
Subjects:
Intranasal esketamine
Treatment-resistant depression
Depression
Real-world data
Cohort study
Compassionate use
Online Access:http://www.sciencedirect.com/science/article/pii/S2666915325000356
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666915325000356

Similar Items